Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Bactiguard Holding AB (publ)
  6. News
  7. Summary
    BACTI B   SE0005878741

BACTIGUARD HOLDING AB (PUBL)

(BACTI B)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Bactiguard : receives payment from Zimmer Biomet

06/30/2021 | 09:21pm EDT

Following successful European regulatory clearance and market launch of Bactiguard-coated Zimmer Biomet trauma implants (ZNN Bactiguard), the initial USD 1 million milestone payment has been released.

"I am excited about our partnership with Zimmer Biomet and proud of the progress we have made thus far", says Cecilia Edström, CEO at Bactiguard

In September 2019, Bactiguard and Zimmer Biomet partnered to develop orthopedic trauma implants with the Bactiguard technology for infection prevention, to prevent post-operative infections. European regulatory clearance was obtained in January 2021, followed by market launch in Europe and other select EMEA markets in June this year.

The partnership is based on an exclusive, global license agreement for orthopedic trauma implants. In addition to the upfront license fee paid by Zimmer Biomet at signing, the agreement includes additional milestone driven payments of USD 2 million - whereof USD 1 million has now been released.

More information on ZNN Bactiguard can be found at: znnbactiguard.com

This information is information that Bactiguard Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below 2021-07-01, at 03.20.

For further information, please contact:
Cecilia Edström, CEO, phone: +46 72 226 23 28

About Bactiguard
Bactiguard is a Swedish medical device company with a mission to save lives. To achieve this mission, we develop and supply infection prevention solutions which reduce the risk of infections and the use of antibiotics. This way, we save significant costs for healthcare and the society at large.

The Bactiguard technology is based on a thin noble metal alloy coating that prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard offers the technology through licence agreements and our BIP (Bactiguard Infection Protection) portfolio of products. Urinary catheters with Bactiguard's coating are market leaders in the USA and Japan through our licensing partner BD. Bactiguard's product portfolio also includes a non-alcoholic product line for wound care and disinfection. It effectively kills viruses, bacteria and fungi while being biocompatible, pH neutral and tissue friendly. The active ingredient hypochlorous acid is the same substance as the body's immune cells use in their defence against infectious organisms.

Bactiguard is in a strong expansion phase in the markets in Europe, China, India and the Middle East through our own product portfolio and by establishing licensing deals in new therapy areas. Bactiguard has about 180 employees around the world. Its headquarters and one of three production facilities are located in Stockholm, the other two in Malaysia. Bactiguard is listed on Nasdaq Stockholm.
 
Read more about Bactiguard www.bactiguard.com

https://news.cision.com/bactiguard-holding-ab--publ-/r/bactiguard-receives-payment-from-zimmer-biomet,c3377643

https://mb.cision.com/Main/9686/3377643/1439247.pdf

https://news.cision.com/bactiguard-holding-ab--publ-/i/bactiguard,c2931974

(c) 2021 Cision. All rights reserved., source Press Releases - English

Stocks mentioned in the article
ChangeLast1st jan.
BACTIGUARD HOLDING AB (PUBL) 4.27% 171 Delayed Quote.14.69%
ZIMMER BIOMET HOLDINGS, INC. 3.23% 150.4 Delayed Quote.-5.44%
All news about BACTIGUARD HOLDING AB (PUBL)
09/21BACTIGUARD : completes a directed new share issue to AMF, raising approximately SEK 228 mi..
AQ
09/14BACTIGUARD : Aniocyn, now available in stores in the Nordic region
AQ
09/11BACTIGUARD : Sepsis always starts with an infection – causes at least 11 M deaths gl..
PU
09/07Bactiguard Holding AB Appoints Anders Göransson as CEO
CI
09/07BACTIGUARD : appoints new CEO
AQ
08/31BACTIGUARD : recruits Chief Licensing Officer to accelerate growth
AQ
08/31Bactiguard Appoints Carl Johan Fredin as Chief Licensing Officer
CI
08/25Bactiguard Announces Extension of Tender Award for Wound Care Products for the Public S..
CI
08/25BACTIGUARD : Extended Malaysian wound care tender
AQ
07/15BACTIGUARD : Interim report for Q2 2021
AQ
More news
Financials
Sales 2020 177 M 20,5 M 20,5 M
Net income 2020 -38,4 M -4,45 M -4,45 M
Net Debt 2020 254 M 29,5 M 29,5 M
P/E ratio 2020 -125x
Yield 2020 -
Capitalization 5 803 M 672 M 673 M
EV / Sales 2019 15,5x
EV / Sales 2020 28,6x
Nbr of Employees -
Free-Float 34,3%
Chart BACTIGUARD HOLDING AB (PUBL)
Duration : Period :
Bactiguard Holding AB (publ) Technical Analysis Chart | BACTI B | SE0005878741 | MarketScreener
Technical analysis trends BACTIGUARD HOLDING AB (PUBL)
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Managers and Directors
Cecilia Marie Edstr÷m Chief Executive Officer & Director
Gabriella Bj÷rknert Caracciolo Chief Financial Officer & Deputy CEO
Nils Thomas von Koch Chairman
Stefan Grass Chief Medical Officer & Deputy CEO
Sathish Subramaniam Chief Operations Officer